RxDoctor Payments Data

James Macdonald, MD

Neurology · Smithfield, NCNPI 1235304825

Payments from drug & device makers

$4,187in general payments, 2019–2025

Across 208 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$722
  • AstraZeneca$331
  • UCB, Inc.$275
  • Lilly USA, LLC$243
  • AbbVie$229
  • GSK$229
  • plus $2K from 34 others

What the payments were for

  • Speaking & faculty fees$1133%
  • Food & beverage$4,07597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,187 in reported general payments places this provider in the 65th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,377
Medicare patients
338
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5016$210,321
IngrezzaValbenazine Tosylate12$97,735
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$96,607
NuplazidPimavanserin Tartrate16$76,364
UbrelvyUbrogepant29$45,931
Aimovig AutoinjectorErenumab-Aooe44$35,167
Nurtec OdtRimegepant Sulfate18$31,889
BotoxOnabotulinumtoxina18$26,341
Dimethyl Fumarate13$23,762
Emgality PenGalcanezumab-Gnlm34$23,709
NourianzIstradefylline12$23,164
Dalfampridine ErDalfampridine18$9,742
Lacosamide44$9,057
Emgality SyringeGalcanezumab-Gnlm13$8,822
Levetiracetam372$6,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$30$210,32116 claims
Neurocrine Biosciences, Inc.Ingrezza$74$97,73512 claims
AbbVieUbrelvy, Botox$229$72,27247 claims
PfizerNurtec Odt, Dilantin$51$35,58440 claims
Kyowa Kirin, Inc.Nourianz$66$23,16412 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$67$4,12649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 566 neurology providers in North Carolina.

Other neurology in Smithfield

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →